Nsengiyumva Bati Daddy1, Luc Malemo Kalisya2, Pascal Gisenya Bagire3, Robert L Watt4, Melissa J Towler5, Pamela J Weathers6. 1. Rwanguba Hospital, Rwanguba, N. Kivu, Democratic Republic of Congo. Electronic address: batidaddy@yahoo.fr. 2. HEAL Africa Hospital, Goma, Democratic Republic of Congo. Electronic address: lucmalemo21@gmail.com. 3. Plesion International Inc., Edmonton, AB, Canada. Electronic address: pbgisenya@gmail.com. 4. Plesion International Inc., Coatesville, PA, 19320 USA. Electronic address: robertwatt121@gmail.com. 5. Worcester Polytechnic Institute, Worcester, MA 01609, USA. Electronic address: eeyore@wpi.edu. 6. Worcester Polytechnic Institute, Worcester, MA 01609, USA.
Abstract
BACKGROUND: Dried leaf Artemisia annua (DLA) has shown efficacy against Plasmodium sp. in rodent studies and in small clinical trials. Rodent malaria also showed resiliency against the evolution of artemisinin drug resistance. PURPOSE: This is a case report of a last resort treatment of patients with severe malaria who were responding neither to artemisinin combination therapy (ACT) nor i.v. artesunate. STUDY DESIGN: Of many patients treated with ACTs and i.v. artesunate during the 6 mon study period, 18 did not respond and were subsequently treated with DLA Artemisia annua. METHODS: Patients were given a dose of 0.5g DLA per os, twice daily for 5d. Total adult delivered dose of artemisinin was 55mg. Dose was reduced for body weight under 30kg. Clinical symptoms, e.g. fever, coma etc., and parasite levels in thick blood smears were tracked. Patients were declared cured and released from hospital when parasites were microscopically undetectable and clinical symptoms fully subsided. RESULTS: All patients were previously treated with Coartem® provided through Santé Rurale (SANRU) and following the regimen prescribed by WHO. Of 18 ACT-resistant severe malaria cases compassionately treated with DLA, all fully recovered. Of the 18, this report details two pediatric cases. CONCLUSIONS: Successful treatment of all 18 ACT-resistant cases suggests that DLA should be rapidly incorporated into the antimalarial regimen for Africa and possibly wherever else ACT resistance has emerged.
BACKGROUND: Dried leaf Artemisia annua (DLA) has shown efficacy against Plasmodium sp. in rodent studies and in small clinical trials. Rodent malaria also showed resiliency against the evolution of artemisinin drug resistance. PURPOSE: This is a case report of a last resort treatment of patients with severe malaria who were responding neither to artemisinin combination therapy (ACT) nor i.v. artesunate. STUDY DESIGN: Of many patients treated with ACTs and i.v. artesunate during the 6 mon study period, 18 did not respond and were subsequently treated with DLA Artemisia annua. METHODS:Patients were given a dose of 0.5g DLA per os, twice daily for 5d. Total adult delivered dose of artemisinin was 55mg. Dose was reduced for body weight under 30kg. Clinical symptoms, e.g. fever, coma etc., and parasite levels in thick blood smears were tracked. Patients were declared cured and released from hospital when parasites were microscopically undetectable and clinical symptoms fully subsided. RESULTS: All patients were previously treated with Coartem® provided through Santé Rurale (SANRU) and following the regimen prescribed by WHO. Of 18 ACT-resistant severe malaria cases compassionately treated with DLA, all fully recovered. Of the 18, this report details two pediatric cases. CONCLUSIONS: Successful treatment of all 18 ACT-resistant cases suggests that DLA should be rapidly incorporated into the antimalarial regimen for Africa and possibly wherever else ACT resistance has emerged.
Authors: Mostafa A Elfawal; Melissa J Towler; Nicholas G Reich; Pamela J Weathers; Stephen M Rich Journal: Proc Natl Acad Sci U S A Date: 2015-01-05 Impact factor: 11.205
Authors: Pamela J Weathers; Patrick R Arsenault; Patrick S Covello; Anthony McMickle; Keat H Teoh; Darwin W Reed Journal: Phytochem Rev Date: 2011-06 Impact factor: 5.374
Authors: Mary H Grace; Carmen Lategan; Rocky Graziose; Peter J Smith; Ilya Raskin; Mary Ann Lila Journal: Nat Prod Commun Date: 2012-10 Impact factor: 0.986
Authors: Mostafa A Elfawal; Melissa J Towler; Nicholas G Reich; Douglas Golenbock; Pamela J Weathers; Stephen M Rich Journal: PLoS One Date: 2012-12-20 Impact factor: 3.240
Authors: John O Suberu; Alexander P Gorka; Lauren Jacobs; Paul D Roepe; Neil Sullivan; Guy C Barker; Alexei A Lapkin Journal: PLoS One Date: 2013-11-14 Impact factor: 3.240
Authors: B M Gruessner; L Cornet-Vernet; M R Desrosiers; P Lutgen; M J Towler; P J Weathers Journal: Phytochem Rev Date: 2019-09-19 Impact factor: 5.374
Authors: Tomasz Czechowski; Mauro A Rinaldi; Mufuliat Toyin Famodimu; Maria Van Veelen; Tony R Larson; Thilo Winzer; Deborah A Rathbone; David Harvey; Paul Horrocks; Ian A Graham Journal: Front Plant Sci Date: 2019-07-30 Impact factor: 5.753
Authors: Yuyong Zhou; Kerry Gilmore; Santseharay Ramirez; Eva Settels; Karen A Gammeltoft; Long V Pham; Ulrik Fahnøe; Shan Feng; Anna Offersgaard; Jakob Trimpert; Jens Bukh; Klaus Osterrieder; Judith M Gottwein; Peter H Seeberger Journal: Sci Rep Date: 2021-07-16 Impact factor: 4.379
Authors: Lisa Gruber; Sara Abdelfatah; Tony Fröhlich; Christoph Reiter; Volker Klein; Svetlana B Tsogoeva; Thomas Efferth Journal: Molecules Date: 2018-04-06 Impact factor: 4.411